Tyra Bioscience (TYRA)
NASDAQ:TYRA
Top Page
Tyra Bioscience
(NASDAQ:TYRA)
Select Model
Select Model
Rating:58Neutral
Price Target:
$40.00
▲(8.96% Upside)
Action:ReiteratedDate:03/05/26
The score is primarily held back by weak financial performance (no revenue, widening losses, and rising cash burn), partially offset by a strong technical uptrend and improved funding flexibility from the $126M equity raise. Valuation remains challenged due to negative earnings and no dividend support.
Positive Factors
Access to capital
The $126M block sale demonstrates durable access to institutional equity capital, materially extending runway for clinical programs without adding meaningful debt. Continued ability to raise equity reduces near-term liquidity risk and supports execution of multi-stage development plans over the next 2-6 months.
Negative Factors
Pre-revenue with widening losses
Being pre-revenue with materially widening losses means continued reliance on external financing until commercialization or partnering. Persistent negative earnings consume equity and constrain reinvestment, increasing the long-term dilution and financing risk if clinical progress stalls.
Read all positive and negative factors
Positive Factors
Negative Factors
Access to capital
The $126M block sale demonstrates durable access to institutional equity capital, materially extending runway for clinical programs without adding meaningful debt. Continued ability to raise equity reduces near-term liquidity risk and supports execution of multi-stage development plans over the next 2-6 months.
Read all positive factors
Tyra Bioscience (TYRA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.98B
Dividend YieldN/A
Average Volume (3M)370.94K
Price to Earnings (P/E)―
Beta (1Y)1.52
Revenue GrowthN/A
EPS Growth-17.01%
CountryUS
Employees60
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.57
Shares Outstanding53,867,115
10 Day Avg. Volume580,167
30 Day Avg. Volume370,944
Financial Highlights & Ratios
PEG Ratio-0.39
Price to Book (P/B)6.05
Price to Sales (P/S)0.00
P/FCF Ratio-16.45
Enterprise Value/Market Cap1.00
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-7.25K
Enterprise Value/Ebitda-16.51
Forecast
1Y Price Target
$50.71Price Target Upside38.14% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-2.36
Revenue Forecast (FY)N/A
Tyra Bioscience Business Overview & Revenue Model
Company Description
Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fib...
How the Company Makes Money
Tyra Biosciences does not sell approved products and, as a clinical-stage biotechnology company, has historically generated limited recurring commercial revenue. Its funding and cash inflows have primarily been supported by capital-raising activit...
Tyra Bioscience Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
24
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -546.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -119.40M | -103.66M | -79.59M | -58.63M | -26.15M |
| Net Income | -119.95M | -86.48M | -69.13M | -55.33M | -26.29M |
Balance Sheet | |||||
| Total Assets | 282.61M | 363.56M | 225.86M | 266.18M | 306.70M |
| Cash, Cash Equivalents and Short-Term Investments | 256.00M | 341.44M | 203.47M | 251.21M | 302.18M |
| Total Debt | 5.81M | 6.22M | 6.50M | 2.62M | 1.18M |
| Total Liabilities | 23.43M | 20.41M | 21.59M | 8.35M | 4.96M |
| Stockholders Equity | 259.18M | 343.15M | 204.26M | 257.83M | 301.74M |
Cash Flow | |||||
| Free Cash Flow | -95.28M | -70.44M | -50.91M | -50.84M | -24.41M |
| Operating Cash Flow | -95.14M | -69.77M | -50.14M | -50.28M | -23.75M |
| Investing Cash Flow | 72.46M | -98.40M | -144.60M | -559.00K | -645.00K |
| Financing Cash Flow | 8.10M | 202.14M | 1.54M | 632.00K | 311.35M |
Tyra Bioscience Technical Analysis
Positive
36.71
Price Trends
32.59
Positive
27.05
Positive
19.40
Positive
Market Momentum
1.46
Positive
59.89
Neutral
48.87
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TYRA, the sentiment is Positive. The current price of 36.71 is above the 20-day moving average (MA) of 35.60, above the 50-day MA of 32.59, and above the 200-day MA of 19.40, indicating a bullish trend. The MACD of 1.46 indicates Positive momentum. The RSI at 59.89 is Neutral, neither overbought nor oversold. The STOCH value of 48.87 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TYRA.
Tyra Bioscience Risk Analysis
Tyra Bioscience disclosed 87 risk factors in its most recent earnings report. Tyra Bioscience reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Tyra Bioscience Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | $1.98B | -13.06 | -34.75% | ― | ― | -17.01% | |
57 Neutral | $866.36M | -3.32 | -282.01% | ― | ― | -13.14% | |
52 Neutral | $5.62B | -6.99 | -29.95% | ― | ― | 12.45% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $1.65B | -15.28 | -64.41% | ― | ― | ― | |
47 Neutral | $1.59B | -5.54 | -57.51% | ― | 48.32% | -1.91% | |
40 Underperform | $89.54M | -3.72 | 264.70% | ― | -58.17% | -116.24% |
* Healthcare Sector Average
TYRA
Tyra Bioscience
36.71
27.05
280.02%
KALV
KalVista Pharmaceuticals
17.14
4.80
38.90%
PVLA
Palvella Therapeutics
120.39
92.63
333.68%
GOSS
Gossamer Bio
0.38
-0.78
-67.16%
NRIX
Nurix Therapeutics
15.44
2.89
23.03%
TERN
Terns Pharmaceuticals
52.86
49.74
1594.23%
Tyra Bioscience Corporate Events
Private Placements and FinancingRegulatory Filings and Compliance
Tyra Bioscience Raises $126 Million in Block Share Sale
Positive
Mar 4, 2026
On March 4, 2026, Tyra Biosciences, Inc. agreed to issue and sell 4,000,000 shares of its common stock to a large investment management firm at $31.50 per share, in a block transaction under its existing at-the-market equity offering program. The ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.